Form 4: Outlook Therapeutics CFO Lawrence Kenyon Buys 5,000 Shares
SEC Form 4 Filing
Lawrence Kenyon, CFO of Outlook Therapeutics, recently purchased 5,000 shares of the company's common stock at a price of $5.6892 per share.
Summary
- On September 26, 2024, Lawrence Kenyon, the Chief Financial Officer of Outlook Therapeutics, Inc., purchased 5,000 shares of common stock.
- The purchase price was $5.6892 per share.
- Following the transaction, Kenyon directly owns 5,946 shares of Outlook Therapeutics.
Sentiment
Score: 7
Explanation: The sentiment is slightly positive due to the CFO's stock purchase, indicating confidence in the company. However, it's a single transaction and doesn't provide a comprehensive view of the company's overall health.
Positives
- The CFO's purchase of company stock could be interpreted as a positive signal about their confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company insider believes the stock is undervalued.
Stakeholder Impact
- The stock purchase by a key executive could positively influence investor sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/13/2024 | Issuer's 1-for-20 reverse stock split |
| 09/26/2024 | Lawrence Kenyon purchased 5,000 shares of common stock |
| 09/30/2024 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.